Our Goal

Helping people with serious medical conditions lead fulfilling lives

At Sunovion Pharmaceuticals Europe Ltd., we focus on the introduction and commercialisation of innovative medicines that improve people's lives, with a current specialisation in mental health.

LATUDA® (lurasidone) for the treatment of schizophrenia

Sunovion currently markets the antipsychotic lurasidone in the UK and selected countries in Europe for the treatment of schizophrenia in adults.

Adverse reactions should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

Adverse reactions should also be reported to Sunovion Pharmaceuticals Europe Ltd. on +44 20 7821 2899.

For more information about lurasidone visit:

Sunovion Pharmaceuticals Europe Ltd is sponsoring a non-interventional, observational study.  Details can be found at http://www.encepp.eu/encepp/viewResource.htm?id=28736

Featured News

21 Nov 2017

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe

16 Nov 2016

Sunovion Pharmaceuticals Europe Ltd. and NewBridge Pharmaceuticals Announce Agreement for Distribution of Latuda® (lurasidone) in the Gulf Cooperation Council Region.

7 June 2016

Sunovion Pharmaceuticals Europe Ltd. and Medicines Optimisation Innovation Centre (MOIC) form a partnership for Mental Health.

Sunovion by the numbers

  • Top 20 One of the fastest-growing among top U.S. pharmaceutical companies*
  • 1,620 employees worldwide
  • 30K employee volunteer hours in 8 years

See how we make a difference